Related Experiment Videos
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab
Anjali V Morales1, Ranjana Advani, Steven M Horwitz
1Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, Stanford, California 94305, USA.
Journal of the American Academy of Dermatology
|September 27, 2008
Summary
Systemic rituximab shows promise as a first-line treatment for indolent cutaneous B-cell lymphoma (CBCL) presenting with multiple lesions. This study found an 87% objective response rate, suggesting rituximab is a viable option when local therapies are unsuitable.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Optimal treatment for indolent primary cutaneous B-cell lymphoma (CBCL), including marginal zone and follicle center lymphomas with multiple lesions, remains undefined.
- Rituximab, a CD20-targeting monoclonal antibody, has shown potential, but its efficacy in CBCL requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of systemic rituximab as a single agent for treating indolent CBCL with multiple lesions.
Main Methods:
- A retrospective analysis of 15 patients with indolent CBCL treated with intravenous rituximab (375 mg/m²).
- Patients received rituximab as a single agent, with a variable maintenance regimen in some cases.
- Response assessment included complete response, partial response, stable disease, and progressive disease, with efficacy endpoints like objective response rate and time to progression.
Main Results:
- The study included 10 patients with follicle center lymphoma and 5 with marginal zone lymphoma.
- An overall objective response rate of 87% was observed (60% complete response, 27% partial response).
- Median follow-up was 36 months, with median time to response, duration of response, and time to progression all at 24 months.
Conclusions:
- Despite limitations including small sample size and retrospective design, the findings suggest rituximab is a reasonable first-line treatment option for indolent CBCL.
- Rituximab may be particularly beneficial for patients with multiple lesions where local treatment is not feasible or desired.
Related Concept Videos
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:15Secondary Lymphoid Organs
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...